Our group aims to develop new T-cell based concepts for cancer immunotherapy that overcome the major challenge of self-tolerance in cancer. To this end, one of our main strategies involves studies of how the immune system from healthy donors can target patient cancer cells. We have a strong focus on the development of new technologies that allow high-throughput identification of therapeutic targets that can evoke immune responses, as lack of immunogenic targets represents a major limitation in therapeutic efficacy. The group furthermore has a strong translational focus and performs penetrating mechanistic analyses in clinical trials together with our clinical partners.
Johanna Olweus was awarded an ERC Consolidator Grant (September 2020-2025) to pursue the goal of utilizing the mechanism of transplant rejection to identify self-reactive, therapeutic TCRs from healthy donors with the project “OUTSOURCE”. In Dec 2021 the group published proof-of-concept for this approach in Nature Biotechnology.
Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Nature, 608 (7922), E20
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
Leukemia, 36 (7), 1887-1897
A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma
Med (N Y), 2 (2), 180-195.e5